| scholarly article | Q13442814 |
| P50 | author | Thibaut Pelat | Q81116239 |
| Michael Hust | Q38323619 | ||
| Christelle Mazuet | Q43113801 | ||
| Arnaud Avril | Q59551434 | ||
| P2093 | author name string | Michel R Popoff | |
| Philippe Thullier | |||
| Dorothea Sesardic | |||
| Nicola Bak | |||
| Christine Rasetti-Escargueil | |||
| Rob Tierney | |||
| Sebastian Miethe | |||
| Siham Chahboun | |||
| P2860 | cites work | Analysis of mass transport-limited binding kinetics in evanescent wave biosensors | Q71543405 |
| Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model | Q73265685 | ||
| Botulinum Toxin as a Biological Weapon: Medical and Public Health Management | Q23832736 | ||
| Properties and use of botulinum toxin and other microbial neurotoxins in medicine | Q23833526 | ||
| Bacterial toxins: a table of lethal amounts | Q24634272 | ||
| Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin | Q27643327 | ||
| Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity | Q28475305 | ||
| Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo | Q28483998 | ||
| Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus | Q28752041 | ||
| Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin | Q29619130 | ||
| Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries | Q30817149 | ||
| Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies | Q30862040 | ||
| Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin | Q31042202 | ||
| Phage display vectors for the in vitro generation of human antibody fragments. | Q31135881 | ||
| Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. | Q33218388 | ||
| Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. | Q33220467 | ||
| High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation | Q33285349 | ||
| Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids | Q33308728 | ||
| Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain | Q33361666 | ||
| Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B | Q33396168 | ||
| Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity | Q33476009 | ||
| Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. | Q33526822 | ||
| Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents | Q33613925 | ||
| Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. | Q33680867 | ||
| Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk | Q33871288 | ||
| Neurotoxins affecting neuroexocytosis | Q33881286 | ||
| The current use of botulinum toxin | Q34003057 | ||
| Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization | Q34034156 | ||
| Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody | Q34038244 | ||
| Clinical recognition and management of patients exposed to biological warfare agents | Q34064997 | ||
| Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies | Q34074842 | ||
| A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model | Q34125366 | ||
| IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. | Q34278966 | ||
| Human botulism immune globulin for the treatment of infant botulism | Q34490632 | ||
| Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin | Q34571717 | ||
| Isolation of antibodies from non-human primates for clinical use. | Q34587231 | ||
| High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. | Q34784806 | ||
| Genetic diversity among Botulinum Neurotoxin-producing clostridial strains | Q35634548 | ||
| Detection of antibodies against botulinum toxins | Q35693987 | ||
| De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. | Q35843022 | ||
| Presynaptic neurotoxins with enzymatic activities | Q37026701 | ||
| Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia | Q37129916 | ||
| Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations | Q37521050 | ||
| Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. | Q37698936 | ||
| Use of botulinum toxin in the neurology clinic | Q37806619 | ||
| Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. | Q38337915 | ||
| Use of IMGT(®) databases and tools for antibody engineering and humanization | Q38495526 | ||
| IMGT/DomainGapAlign: the IMGT® tool for the analysis of IG, TR, MH, IgSF, and MhSF domain amino acid polymorphism | Q38496739 | ||
| Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering | Q39922718 | ||
| Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins | Q40007124 | ||
| Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. | Q40158057 | ||
| Growth of clostridia and preparation of their neurotoxins. | Q40935923 | ||
| Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis | Q41485301 | ||
| Sequence homology and structural analysis of the clostridial neurotoxins | Q41695875 | ||
| A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering | Q41894470 | ||
| The humanness of macaque antibody sequences | Q44429848 | ||
| Systemic toxicity of botulinum toxin by intramuscular injection in the monkey | Q46083035 | ||
| Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. | Q47681429 | ||
| Induction of acute lung injury after intranasal administration of toxin botulinum a complex | Q47819597 | ||
| Analyzing the "degree of humanness" of antibody sequences. | Q51022916 | ||
| A label-free biosensor assay for botulinum neurotoxin B in food and human serum. | Q51552542 | ||
| Construction of human antibody gene libraries and selection of antibodies by phage display | Q56891541 | ||
| Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies | Q58318425 | ||
| Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve–hemidiaphragm: Improved precision with in-bred mice | Q58318428 | ||
| Botulinum type A toxin neutralisation by specific IgG and its fragments: A comparison of mouse systemic toxicity and local flaccid paralysis assays | Q58318435 | ||
| Hypersensitivity reactions associated with botulinal antitoxin | Q70653883 | ||
| Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin | Q71340512 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1161-1177 | |
| P577 | publication date | 2015-09-18 | |
| P1433 | published in | Monoclonal Antibodies | Q6714645 |
| P1476 | title | Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B | |
| P478 | volume | 7 |
| Q42108314 | Affinity biosensors using recombinant native membrane proteins displayed on exosomes: application to botulinum neurotoxin B receptor. |
| Q47369432 | Construction of Macaque Immune-Libraries. |
| Q36112959 | Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B |
| Q41416393 | Phage display-derived human antibodies in clinical development and therapy |
| Q36023082 | Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. |
| Q33845127 | Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations |
| Q38696776 | SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E. |
| Q99591478 | Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors |
| Q37285685 | Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library |
| Q45235847 | The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies |
| Q47373283 | Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques. |
Search more.